TABLE 2.

Characteristics in children with and without CSF shunt reinfection at 6 months

	No. of Patients (%) or Median (IQR)
Factor	w/o Reinfection	w/ Reinfection	p Value
no. of patients	575	100
initial CSF shunt placement
age			0.37
≤30 days	197 (34.3)	36 (36.0)
1–6 mos	168 (29.2)	32 (32.0)
6–48 mos	136 (23.7)	16 (16.0)
≥48 mos	74 (12.9)	16 (16.0)
sex			0.94
male	308 (53.6)	54 (54.0)
female	267 (46.4)	46 (46.0)
race/ethnicity			0.78
non-Latino white	274 (50.4)	47 (49.5)
non-Latino black	136 (25.0)	24 (25.3)
Latino	64 (11.8)	14 (14.7)
Asian	12 (2.2)	3 (3.2)
other	58 (10.7)	7 (7.4)
payer			0.64
public	294 (51.1)	55 (55.0)
private	164 (28.5)	24 (24.0)
other	117 (20.3)	21 (21.0)
indication for shunt placement
IVH	66 (11.5)	11 (11.0)	0.89
myelomeningocele	66 (11.5)	6 (6.0)	0.10
CNS tumor	50 (8.7)	10 (10.0)	0.67
meningitis	14 (2.4)	4 (4.0)	0.37
trauma	10 (1.7)	0 (0.0)	0.18
comorbidities			0.63
none	392 (68.2)	67 (67.0)
1	151 (26.3)	25 (25.0)
≥2	35 (5.6)	8 (8.0)
distal shunt location			0.96
VP	563 (97.9)	98 (98.0)
other	12 (2.1)	2 (2.0)
initial CSF shunt infection
age			0.67
≤30 days	19 (3.3)	4 (4.0)
1–6 mos	200 (34.3)	40 (40.0)
6–48 mos	241 (41.9)	40 (40.0)
≥48 mos	115 (20.0)	16 (16.0)
interval CSF shunt revisions	1 (1, 2)	1 (1, 2)	0.43
interval time from initial shunt placement (days)	79 (28–360)	50 (22–229)	0.06
interval time from last op (days)	34 (17–100)	23 (14–50)	0.03
hospital vol			0.77
1–20	28 (4.9)	7(7.0)
21–40	155 (27.0)	31 (31.0)
41–60	292 (50.8)	46 (46.0)
≥61	100 (17.4)	16 (16.0)
surgeon vol			0.50
≤10	181 (31.5)	32 (32.0)
11–20	223 (38.8)	42 (42.0)
21–30	97 (16.9)	11 (11.0)
>30	74 (12.9)	15 (15.0)
op approach to initial shunt infection (483 patients)
shunt removal/new shunt placement	242 (58.7)	44 (62.0)	0.61
externalization	47 (11.4)	12 (16.9)	0.19
nonop management	49 (11.9)	15 (21.1)	0.03
complete shunt removal	74 (18.0)	0 (0.0)	<0.001
duration of intravenous antibiotic use (days)	9 (0–16)	7.5 (0–17)	0.98